Dr. Frederic B. Newman, MD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of Florida College of Medicine (1986)
- Years since graduation
- 40
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 608
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1986Medical school: University of Florida College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
FL license ME126998 · CA license G71391
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sacred Heart Hospital Pensacola, FL
- Baptist Hospital Pensacola, FL
- Gulf Breeze Hospital Gulf Breeze, FL
- North Okaloosa Medical Center Crestview, FL
Medical groups
- Gastroenterology Associates of Pensacola PA (41 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 608
- Services billed
- 8,190
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, infliximab, excludes biosimilar, 10 mg | 1,370 | 13 |
| Biopsy of large bowel using a flexible endoscope | 141 | 139 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 97 | 57 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 86 | 83 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 55 | 55 |
| Established patient office or other outpatient visit, 20-29 minutes | 52 | 46 |
| Established patient office or other outpatient visit, 30-39 minutes | 49 | 44 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 43 | 43 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 37 | 37 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 37 | 37 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pantoprazole Sodium Other prescribers in Pensacola, FL | 223 |
| Linzess (linaclotide) Other prescribers in Pensacola, FL | 81 |
| Omeprazole Other prescribers in Pensacola, FL | 80 |
| Famotidine Other prescribers in Pensacola, FL | 65 |
| Gavilyte-G (peg3350/sod sulf,bicarb,cl/kcl) Other prescribers in Pensacola, FL | 41 |
| Sucralfate Other prescribers in Pensacola, FL | 28 |
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in Pensacola, FL | 28 |
| Ondansetron Hcl Other prescribers in Pensacola, FL | 26 |
| Dicyclomine Hcl Other prescribers in Pensacola, FL | 25 |
| Budesonide Dr (budesonide) Other prescribers in Pensacola, FL | 21 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 17 payments worth $308 in total to this clinician.
| AbbVie Inc. | $108 |
|---|---|
| Genzyme Corporation | $44.45 |
| Takeda Pharmaceuticals U.S.A., Inc. | $43.14 |
| Janssen Biotech, Inc. | $40.83 |
| Ardelyx, Inc. | $33.81 |
| Pfizer Inc. | $29.07 |
| Phathom Pharmaceuticals, Inc. | $8.67 |
| Food and Beverage | $308 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $26,112 in research payments for these studies, mostly to the institutions running them.
- Roche Cancer Screening Collection Study
Genentech, Inc. - A study of TAK-062 in treatment of active celiac disease in participants attempting a gluten-free diet
Takeda Pharmaceuticals U.S.A., Inc. - A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
Eli Lilly and Company · Active, not recruiting · NCT04232553
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.